| Literature DB >> 35746172 |
Muna E Raypah1, Asma Nadia Faris2, Mawaddah Mohd Azlan2, Nik Yusnoraini Yusof2, Fariza Hanim Suhailin3, Rafidah Hanim Shueb2,4, Irneza Ismail5, Fatin Hamimi Mustafa2.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is a worldwide health anxiety. The rapid dispersion of the infection globally results in unparalleled economic, social, and health impacts. The pathogen that causes COVID-19 is known as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A fast and low-cost diagnosis method for COVID-19 disease can play an important role in controlling its proliferation. Near-infrared spectroscopy (NIRS) is a quick, non-destructive, non-invasive, and inexpensive technique for profiling the chemical and physical structures of a wide range of samples. Furthermore, the NIRS has the advantage of incorporating the internet of things (IoT) application for the effective control and treatment of the disease. In recent years, a significant advancement in instrumentation and spectral analysis methods has resulted in a remarkable impact on the NIRS applications, especially in the medical discipline. To date, NIRS has been applied as a technique for detecting various viruses including zika (ZIKV), chikungunya (CHIKV), influenza, hepatitis C, dengue (DENV), and human immunodeficiency (HIV). This review aims to outline some historical and contemporary applications of NIRS in virology and its merit as a novel diagnostic technique for SARS-CoV-2.Entities:
Keywords: COVID-19; SARS-CoV-2; chemometrics; diagnostics; near-infrared spectroscopy; viruses
Mesh:
Year: 2022 PMID: 35746172 PMCID: PMC9229781 DOI: 10.3390/s22124391
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.847
Figure 1SARS-CoV-2 structure.
Figure 2Electromagnetic spectrum highlighting IR and NIR regions.
Figure 3Overtones and combinations of NIR band assignments.
Figure 4Configuration of UV-Vis/NIR spectroscopy system.
Figure 5Flowchart showing commonly used methods and models in NIR analysis.
A summary of studies reporting the viral infections using NIRS technology.
| Detected Virus | Samples | Chemometric Analysis | Reference Methods | Wavelength Range (nm) | Limit of Detection | Sensitivity | Specificity |
|---|---|---|---|---|---|---|---|
| HIV-1 [ | Plasma | PLS and leave-out cross-validation | PCR and ELISA | 600–1000 | Not applicable | Sensitive at 970 nm, R2 = 0.8555 | - |
| HIV-1 [ | Plasma | PCA and SIMCA | PCR | 600–1100 | Not applicable | Sensitive at 970 nm and between 1000 nm to 1100 nm | Could differentiate between HIV-1 patients and healthy |
| Human influenza virus [ | Nasal aspirates | PCA and SIMCA | Immunochromatography | 600–1100 | Not applicable | Sensitive at 970 nm | >93% |
| Human influenza virus [ | Nasal mucosal | Kruskal–Wallis test and Dunn’s | Immunochromatography | 600–1100 | Not applicable | Sensitive at 970 nm | - |
| DENV [ | Human blood | Not applicable_ | Serological test | 400–900 | Not applicable | Sensitive at 540 nm and 580 nm | Obvious difference between DENV, normal, and other viruses from 500–600 nm |
| Hepatitis C [ | Human blood | Not applicable | Serological test | 400–900 | Not applicable | Sensitive at 700 nm | Obvious difference between hepatitis C, normal, and other viruses from 700–1000 nm |
| Wolbachia pipientis in Ae. aegypti mosquito [ | Heads and thoraces | PLS | Not applicable | 500–2350 | Not applicable | Sensitive at 1400 nm and 1900 nm | >96.6% between different strains |
| ZIKV-infected Ae. aegypti mosquitoes [ | Heads and thoraces | Cross-validation, Regression coefficient and PLS | RT-qPCR | 350–2500 | Not applicable | Sensitive at 1900 nm | >94% |
| ZIKV-, CHIKV, and Wolbachia-infection [ | Heads and thoraces | PLS and PLSDA | RT-qPCR | 350–2500 | Not applicable | Sensitive at 1400 nm and 1900 nm | >96% |
Recent studies of COVID-19 detection using spectroscopy at mid-infrared and UV-VIS wavelength.
| Samples | Chemometric Analysis | Reference Methods | Wavelength Range (nm) | Limit of Detection | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| RNA from swab test [ | PLS, PCA, machine learning | RT-PCR | 1250–16,667 nm | 10 copies/μL | 97%, Sensitive at 2352 nm and at Mid IR region | 98.3% between positive and negative samples |
| SARS-CoV-2 from saliva [ | PCA, PLS-DA, Monte Carlo Double Cross Validation | RT-qPCR | 2500–10,000 nm | Not applicable | 93% | 82% between positive and negative samples |
| Swab fluid [ | PLS and cosine k-nearest neighbors (KNN) | RT-PCR | Mid IR | Not applicable | 84–87% | 64–66% between positive and negative samples |
| SARS-CoV-2 isolate [ | Not applicable | Not applicable | UV-VIS | Not applicable | Sensitive at 280 nm | Not applicable |
| RNA from swab test [ | Genetic Algorithm-LDA | RT-PCR | Mid IR | 1582 copies/mL | 89% between positive and negative samples |
Figure 6Schematic drawing of steps to detect SARS-CoV-2 using the NIRS technique.
Figure 7Proposed steps of an NIRS device development for COVID-19 detection.
Figure 8Proposed implementation of NIRS device of COVID-19 in IoT application.